Product guide · Restricted substance

Nucleon NAD+ 500 mg Pen – Cellular Energy & Longevity Support

Peptide product from Nucleon Nutrition, injectable. This guide sets out what the manufacturer states about the composition of Nucleon NAD+ 500 mg Pen, what independent research says about its main ingredient, and the safety and regulatory points that apply. It contains substances that are not authorised as food or medicine in the EU. This guide is educational: it does not recommend use and gives no directions for use.

Educational guide · Sources checked 4 November 2026 · 3 references

Back to the product

Named ingredients: 1
Amounts stated: All
Status: Restricted substance
Evidence summaries: 1

Overview

Manufacturer information

Nucleon NAD+ 500 mg Pen contains NAD+: 500 mg per pen.

Ingredients & composition

Manufacturer information

Ingredient	Amount
NAD+	500 mg per pen

Scientific background

Independent research

NAD+ and NMN

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in energy metabolism whose levels decline with age. NMN (nicotinamide mononucleotide) and nicotinamide riboside are precursors that the body converts to NAD+.

Research evidence

Independent research

NAD+ and NMN

A 2026 systematic review of trials of oral NMN found good short-term tolerability but no clear broad metabolic benefits, with preliminary signals on blood pressure and insulin resistance¹. Evidence for injected or nasal NAD+ products is very limited.

Evidence limitations

Independent research

No published study has tested this specific product; the research summarised here concerns the ingredient itself.

NAD+ and NMN

Trials are short and small; larger, longer trials are needed to confirm efficacy and long-term safety¹.

Safety & potential risks

Independent research

NAD+ and NMN

Short-term oral NMN was well tolerated in trials¹. Injectable NAD+ products are not quality-controlled medicines.

Regulatory status

GIGACULT product information

This product contains an ingredient that is restricted or not authorised as a food supplement in some or all EU markets. No health benefits or directions for use are given.

Regulation and sport

NAD+ and NMN

NMN and NAD+ are not authorised novel foods in the EU². Injectable NAD+ products are not authorised medicines³.

Scientific references

Yang W, Huang J, Tang Z, et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients. 2026;18. PubMed 42514320
Regulation (EU) 2015/2283 on novel foods. Official Journal of the European Union. Source
Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. Source

Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.

The product